VYNE Therapeutics Total Liabilities and Share Holders Equity 2016-2024 | VYNE

VYNE Therapeutics total liabilities and share holders equity from 2016 to 2024. Total liabilities and share holders equity can be defined as the total of all liabilities and shareholders' equity.

VYNE Therapeutics Total Liabilities and Share Holders Equity 2016-2024 | VYNE

VYNE Therapeutics total liabilities and share holders equity from 2016 to 2024. Total liabilities and share holders equity can be defined as the total of all liabilities and shareholders' equity.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$88.3B
Takeda Pharmaceutical (TAK)$46.6B
Merck (MKGAF)$23B
Astellas Pharma (ALPMY)$21.6B
Sandoz Group AG (SDZNY)$18.1B
Summit Therapeutics (SMMT)$16.5B
United Therapeutics (UTHR)$15.9B
Shionogi (SGIOY)$13.3B
Neurocrine Biosciences (NBIX)$11.7B
Catalent (CTLT)$10.9B
Orion OYJ (ORINY)$7.7B
Revolution Medicines (RVMD)$7.3B
Jazz Pharmaceuticals (JAZZ)$6.8B
Ionis Pharmaceuticals (IONS)$6B
Hikma Pharmaceuticals Plc (HKMPF)$5.7B
Madrigal Pharmaceuticals (MDGL)$4.6B
Corcept Therapeutics (CORT)$4.5B
Crinetics Pharmaceuticals (CRNX)$4B
Dyne Therapeutics (DYN)$3.5B
PTC Therapeutics (PTCT)$2.9B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Arrowhead Pharmaceuticals (ARWR)$2.4B
Catalyst Pharmaceuticals (CPRX)$2.4B
Recursion Pharmaceuticals (RXRX)$2B
Soleno Therapeutics (SLNO)$1.9B
Centessa Pharmaceuticals (CNTA)$1.8B
Xencor (XNCR)$1.6B
Harrow (HROW)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.6B
Cassava Sciences (SAVA)$1.5B